Skip to main content
KT

Karios Technologies

Karios Technologies develops TissueShield™, a hydrogel platform designed to prevent postsurgical adhesions and scar tissue formation, particularly in cardiac surgeries. This technology addresses the significant risk of complications and increased mortality associated with adhesions that can occur after major surgical procedures.

Houston, United StatesFounded 20204100+ followers
Updated 4 months ago

Funding

$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Postsurgical adhesions, or scar tissue that fuses tissues and organs together, are a common complication following major surgeries. These adhesions can lead to increased rates of injury and mortality during reoperations and negatively impact patient outcomes. Current solutions are inadequate to address this significant unmet need in surgery.

Solution

Karios Technologies is developing TissueShield™, a hydrogel platform technology designed to prevent postsurgical adhesions and scar tissue formation. TissueShield™ is intended for various surgical applications, with an initial focus on cardiac surgeries, including congenital heart defects in children and procedures with a high likelihood of repeat operations, such as heart transplants and ventricular assist device implants. The hydrogel acts as a barrier, preventing tissues and organs from fusing together during the healing process. Karios Technologies aims to improve patient outcomes and reduce the risks associated with postsurgical adhesions through this innovative approach.

Target Audience

The primary target audience includes surgeons performing cardiac surgeries, particularly those involving congenital heart defects in children and procedures with a high likelihood of repeat operations.

Features

  • Hydrogel platform technology for adhesion prevention
  • Designed for various surgical applications
  • Initial focus on cardiac surgeries
  • Aims to reduce injury and mortality rates during reoperations
  • Collaboration of chemists, bioengineers, and surgeons
This profile is AI-generated and may contain inaccuracies.